AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

News originally published by

November 12, 2026, 08:40 GMT

Increasing Adoption of AI-Powered Drug Development, Machine Learning Technologies, and Investments in Pharmaceutical Research Accelerate Global Market Growth. Copy Sub-Headline

Burlingame, CA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- The Global AI in Drug Discovery Market is estimated to be valued at USD 3,240.0 million in 2026 and is projected to reach USD 15,536.2 million by 2033, registering a compound annual growth rate (CAGR) of 25.1% during 2026–2033. Market growth is primarily driven by increasing public investments in AI-enabled biomedical research, growing adoption of artificial intelligence and machine learning technologies in pharmaceutical research, and rising demand for faster and more cost-effective drug development processes. Additionally, expanding government funding for AI-driven healthcare innovation, increasing collaborations between pharmaceutical companies and AI technology providers, and advancements in predictive modeling, molecular screening, and drug candidate identification are supporting the expansion of the global AI in drug discovery market.

Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/10138

Global AI in Drug Discovery Market Key Takeaways

Software is expected to dominate the global AI in drug discovery market with a share of 66.8% in 2026.

Based on technology, machine learning is projected to account for 47.6% of the AI in drug discovery market share in 2026.

By drug discovery process, hit identification and screening is slated to hold a market share of 26.1% in 2026.

North America is projected to dominate the global market with a 51.6% share in 2026, owing to strong pharmaceutical R&D investments, advanced healthcare infrastructure, and early adoption of AI technologies.

Asia Pacific, registering a CAGR of 27.2%, is poised to emerge as the fastest growing market for AI in drug discovery solutions during the forecast period, thanks to expanding pharmaceutical industries, rising investments in AI-driven research, and growing government support for drug discovery innovation.

Rising Use of AI in Early Drug Research Drives Market Growth

Coherent Market Insights' latest AI in drug discovery market analysis outlines major factors spurring industry growth. These include increasing adoption of AI in pharmaceutical research, growing investments in AI-powered drug discovery platforms, and rising demand for faster and more cost-effective drug development.

Drug discovery involves several time-consuming steps, from finding a suitable biological target to testing potential compounds. Pharmaceutical companies are increasingly using artificial intelligence to handle parts of this work. AI tools can study large biological datasets, identify possible drug targets, and screen chemical compounds to help researchers select promising candidates.

This growing use of AI is encouraging investment in drug discovery platforms. For instance, in May 2026, QIAGEN and NVIDIA announced a collaboration to combine curated biomedical data with accelerated computing and graph-based AI. The initiative aims to help researchers identify disease mechanisms, therapeutic targets, and biomarkers. Such collaborations are expected to support wider use of AI in pharmaceutical research.

Rising prevalence of chronic and complex diseases, including cancer, cardiovascular disorders, and neurological conditions, is increasing demand for new treatment options. AI-powered platforms can help researchers analyze disease-related biological data, identify potential therapeutic targets, and explore new drug candidates. This is creating further opportunities for AI applications in drug discovery, particularly in targeted drug development and precision medicine.

High Development Costs and Data Quality Issues Restrain Market Growth

The global AI in drug discovery market outlook remains positive due to rising adoption of artificial intelligence in pharmaceutical research and growing investments in AI-powered drug development platforms. However, high development costs and data quality issues may limit market growth to some extent during the forecast period.

Developing and using AI drug discovery systems requires significant investment in computing infrastructure, software, and skilled professionals. Smaller biotechnology companies and research institutions may find these costs difficult to manage, thereby slowing down overall AI in drug discovery market growth.

AI models also depend on reliable training data. Incomplete or inconsistent biological and chemical datasets can affect the accuracy of predictions and make it harder to validate research results. These factors may slow adoption, particularly among organizations with limited resources.

Growing Pharmaceutical Investments Creating Lucrative Market Opportunities

Pharmaceutical companies in the contemporary world are investing in AI infrastructure and partnerships to improve their research capabilities. These investments create opportunities for software providers and AI developers offering tools for molecular design, target identification, and compound screening.

In March 2026, Roche expanded its AI infrastructure through the deployment of 2,176 NVIDIA Blackwell GPUs, taking its total hybrid-cloud AI infrastructure to more than 3,500 GPUs. The infrastructure is intended to support the development of new therapeutics and diagnostics. Such investments show how pharmaceutical companies are building computing capacity to use AI across research and development.

Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/10138

Emerging AI in Drug Discovery Market Trends

Rising use of generative AI for molecule design is a key trend in the AI in drug discovery market. Generative AI is helping researchers design new molecules with selected properties instead of relying only on screening existing compounds. This can expand the range of candidates considered during early research and support lead optimization. It can also help researchers explore chemical structures that may not be identified through conventional screening approaches.

Growing adoption of multimodal AI for biological data analysis is supporting market growth. Drug discovery involves data from genomics, proteins, chemical structures, and scientific studies. AI models that combine these different data types can help researchers identify connections between diseases and potential drug targets. This approach can also improve the analysis of complex biological relationships and support target identification.

Increasing partnerships between pharmaceutical companies and technology providers are supporting the adoption of AI in drug discovery. These collaborations allow pharmaceutical companies to access advanced AI models, computing infrastructure, and specialized expertise without developing every capability internally. For example, Novo Nordisk and Anthropic announced a collaboration in September 2026 to apply AI models to selected research and development workflows. Such partnerships are expanding the use of AI across pharmaceutical research.

Growing focus on AI model validation is shaping the AI in drug discovery market. AI-generated predictions still need to be tested before they can guide important drug development decisions. Companies are therefore paying greater attention to model accuracy, data quality, reproducibility, and experimental validation. Regulatory guidance is also helping establish expectations for the use of AI in drug development, supporting greater confidence in these technologies.

Analyst’s View

“The global AI in drug discovery market is expected to benefit from growing pharmaceutical investment and improvements in machine learning and generative AI. Software platforms that support target identification, virtual screening, and molecule design are likely to attract strong demand. However, companies will need to address data quality, model validation, and development costs to turn AI-generated predictions into reliable research outcomes,” said a senior CMI analyst.

Current Events and Their Impact on the AI in Drug Discovery Market

Event

Description and Impact

FDA and EMA Issue Common AI Principles (January 2026)

Description: The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly released ten guiding principles for the use of artificial intelligence in drug development on January 14, 2026. The principles cover human oversight, data governance, model development, performance assessment, and risk management.

Impact: These principles provide pharmaceutical companies with a common reference for adopting AI in drug research and development. They can encourage the use of reliable AI models, strengthen regulatory confidence, and support wider adoption of AI across the drug development lifecycle.

FDA Issues Final ICH M15 Guidance (June 2026)

Description: The FDA recently announced the final ICH M15 guidance on model-informed drug development (MIDD). It provides recommendations for planning, evaluating, and documenting evidence generated through computational models.

Impact: The The guidance establishes a harmonized framework for assessing model-based evidence in drug development. It can help pharmaceutical companies use computational modeling more consistently, improve regulatory interactions, and support informed decisions during drug development.

Competitor Insights

Key companies in the AI in drug discovery market report include:

Schrödinger, Inc.
Insilico Medicine
Recursion Pharmaceuticals, Inc.
Isomorphic Labs Limited
XtalPi Inc.
insitro, Inc.
BenevolentAI
Generate Biomedicines, Inc.
Owkin, Inc.
Atomwise, Inc.

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/10138

Key Developments

In March 2026, Roche expanded its AI infrastructure with 2,176 NVIDIA Blackwell GPUs. The new infrastructure is designed to support the development of therapeutics and diagnostics.

In May 2026, QIAGEN and NVIDIA announced a collaboration to use graph-based AI and curated biomedical knowledge for identifying disease mechanisms, therapeutic targets, and biomarkers.

In September 2026, Novo Nordisk and Anthropic announced a collaboration to apply AI models to selected research and development workflows, with the aim of supporting the discovery and development of new medicines.

Market Segmentation

Material Type Insights (Revenue, USD Bn, 2021 - 2033)
- Cement and Concrete
- Metals and Steel Materials
- Bricks and Blocks
- Glass Materials
- Wood and Engineered Wood
- Insulation Materials
- Others
Product Type Insights (Revenue, USD Bn, 2021 - 2033)
- Structural Materials
- Finishing Materials
- Insulation and Protective Materials
- Decorative Materials
Application Insights (Revenue, USD Bn, 2021 - 2033)
- Residential Construction
- Commercial Construction
- Infrastructure Development
- Industrial Construction
End User Insights (Revenue, USD Bn, 2021 - 2033)
- Construction Companies
- Contractors and Builders
- Government Infrastructure Projects
- Individual Consumers
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Direct Sales
- Dealers and Distributors
- Online Sales
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa

Generative AI in Healthcare Market Size, Share, Trends & Opportunities for 2026-2033

Artificial Intelligence in Healthcare Market Analysis and Forecast for 2026-2033

Mr. Shah
Coherent Market Insights
533 Airport Boulevard,
Suite 400, Burlingame,
CA 94010, United States
US: + 12524771362
UK: +442039578553
AUS: +61-8-7924-7805
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.